PTQ/SB/21 (09-08) Approved for use through 10/31/2008, OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE idet the Paperwork Reduction Act of 1995, no person are required to rescond to ction of information unless it displays a velid OMB control number. Application Number 10/898,671 TRANSMITTAL Filling Date October 28, 2003 First Named Inventor FORM Robert D. Ivarie Art Unit Examiner Name Sumesh Kaushal (to be used for all correspondence after initial filing) Attorney Docket Number AVI-000CQN Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Finel Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below); Form PTO/SB/47 - 1 page Request for Refund Express Abandonment Request Form PTO/SB/122 - 1 page Part B-Fees Transmittel - 1 page CD, Number of CD(s) Information Disclosure Statement 4. Comments on Examiner's Reasons for Allowance - 2 pgs Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Synageva BioPharma Corp. Signature Printed name Kyle Yesland Date Reg. No. March 10, 2009 45,526 CERTIFICATE OF TRANSMISSION/MAILING I hereby cartify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including pathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

Merch 10, 2009

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Kyle Yesiand

Typed or printed name

Appl. No. 10/695,671

## <u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

Appl. No.

10/696,671

Applicant

Ivarie et al

Filed

0 + 1 = 28 200

Title

October 28, 2003
TRANSGENIC CHICKENS THAT LAY EGGS CONTAINING

**EXOGENOUS PROTEINS** 

TC/A.U.

1633

Examiner

KAUSHAL, SUMESH

Docket No.

AVI-000CON

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Issue Fee, Honorable Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on or before:

Date\_\_\_\_

Signature

Name Kyle Yeshand

## COMMENTS ON EXAMINER'S REASONS FOR ALLOWANCE

Mail Stop: Issue Fee

Honorable Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## Dear Sir:

Applicant agrees that the limitations recited in the Examiner's Reasons for Allowance are not taught or suggested by the art of record, and that the claims are patentable for at least the reasons stated in the Reasons for Allowance, which are sufficient for allowance of those claims. Applicant does not concede that the stated reasons are the only grounds for patentability of the allowed claims, that limitations excluded from the Reasons for Allowance are taught or suggested by the art of record and that all of the limitations are necessary for patentability of the allowed claims or other claims directed to the disclosed subject matter. Applicant does not concede that claims canceled in the

Appl. No. 10/696,671

course of prosecution were not patentable and applicant reserves the right to pursue such canceled claims, for example, in one or more related applications.

Respectfully submitted,

Kyle Yesland, Telephone: 706-227-1170

Attorney for Applicant

Reg. No. 45,526

Synageva BioPharma Corp.

111 Riverbend Road Athens, Georgia 30605